HARMONY BIOSCIENCES ANNOUNCES APPLICATIONS OPEN MARCH 18 FOR 2022 PATIENTS AT THE HEART PROGRAM
Harmony Biosciences announced the opening of applications for its Patients at the Heart Program on March 18, 2022, supporting nonprofit organizations addressing challenges faced by individuals with rare neurological diseases, particularly those experiencing excessive daytime sleepiness (EDS). Since its launch in 2019, the program has awarded over $230,000 to patient-centric initiatives. The 2022 application periods are March 18 to May 20 and May 31 to August 19. Harmony aims to enhance community support for patients and their families.
- Opened applications for Patients at the Heart Program, supporting nonprofit initiatives.
- Program has funded over $230,000 since 2019 for patient-centered projects.
- Focus on improving lives of those with rare neurological diseases and EDS.
- None.
Funding supports the comprehensive needs of people affected by rare neurological diseases
PLYMOUTH MEETING, Pa., March 17, 2022 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for people living with rare neurological diseases, today announced applications open on "World Sleep Day", Friday, March 18, 2022, for its Patients at the Heart Program. This funding opportunity is open to nonprofit organizations that are working to support and address the challenges of people living with sleep disorders and rare neurological diseases who experience excessive daytime sleepiness (EDS).
"With this program, we are reinforcing our commitment to supporting the comprehensive needs of people affected by rare neurological diseases, including sleep disorders, and their families," said Cate McCanless, Harmony's Chief Corporate Affairs Officer. "By understanding the unique challenges faced by those in the rare disease community and providing support, we are able to meet these needs with empathy and make a positive impact."
Applications should focus on one or more of the following categories:
- Programs that support persons with rare neurological diseases to live fuller, more engaged lives
- Programs that address the psychosocial challenges faced by persons with sleep disorders or rare neurological diseases who experience EDS, or their caregivers
- Programs that improve the overall support of family members of persons living with rare neurological diseases
- Creation of educational materials to increase awareness and decrease time to diagnosis of rare neurological diseases
Patients at the Heart underscores Harmony's ongoing commitment to support the comprehensive needs of people affected by rare neurological diseases. Since its launch in 2019, the program has funded more than
Harmony has two open application periods for Patients at the Heart in 2022: Friday, March 18, 2022 through Friday, May 20, 2022, and from Tuesday May 31, 2022 through Friday, August 19, 2022. Notification will be sent to awardees by July and October 2022, respectively. For more information, please visit https://www.harmonybiosciences.com/funding-programs/patients-at-the-heart for a program overview document and application. Applications can be submitted to patientsattheheart@harmonybiosciences.com.
About Harmony Biosciences
Harmony Biosciences is a commercial stage pharmaceutical company headquartered in Plymouth Meeting, PA. The Company was established by Paragon Biosciences, LLC, and is focused on providing novel treatment options for people living with rare neurological diseases who have unmet medical needs. For more information on Harmony, please visit the company's website: www.harmonybiosciences.com.
Harmony Biosciences Media Contact:
Nancy Leone
215-891-6046
nleone@harmonybiosciences.com
Harmony Biosciences Investor Contact:
Patti Bank
ICR Westwicke
415-513-1284
ir@harmonybiosciences.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/harmony-biosciences-announces-applications-open-march-18-for-2022-patients-at-the-heart-program-301503511.html
SOURCE Harmony Biosciences
